Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Assets (2016 - 2026)

Aytu Biopharma has reported Assets over the past 15 years, most recently at $122.0 million for Q4 2025.

  • Quarterly Assets rose 4.97% to $122.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.0 million through Dec 2025, up 4.97% year-over-year, with the annual reading at $124.2 million for FY2025, 5.15% up from the prior year.
  • Assets was $122.0 million for Q4 2025 at Aytu Biopharma, down from $125.0 million in the prior quarter.
  • Over five years, Assets peaked at $265.7 million in Q2 2021 and troughed at $115.8 million in Q3 2024.
  • The 5-year median for Assets is $132.9 million (2023), against an average of $149.3 million.
  • Year-over-year, Assets skyrocketed 73.31% in 2021 and then plummeted 48.2% in 2022.
  • A 5-year view of Assets shows it stood at $223.8 million in 2021, then crashed by 36.81% to $141.4 million in 2022, then decreased by 7.2% to $131.2 million in 2023, then fell by 11.45% to $116.2 million in 2024, then grew by 4.97% to $122.0 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Assets are $122.0 million (Q4 2025), $125.0 million (Q3 2025), and $124.2 million (Q2 2025).